【BMS、元米代表GKケイシー・ケラー氏と連携──リンパ腫体験を公表】

✔ ケラー氏が非ホジキンリンパ腫との闘病を初公表
✔ CD19標的CAR-T「Breyanzi」による治療経験を共有
✔ 世界がんデーに合わせた啓発施策

Breyanziは患者自身のT細胞を用いる個別化CAR-T療法。再発・難治性B細胞リンパ腫など複数適応で承認済み。
細胞療法へのアクセス向上と認知拡大を後押し。
#BMS #Breyanzi #CART #リンパ腫 #WorldCancerDay

FDA Approves Lisocabtagene Maraleucel for Relapsed/Refractory Marginal Zone Lymphoma - OncoDaily FDA approves lisocabtagene maraleucel for relapsed/refractory marginal zone lymphoma based on TRANSCEND FL-MZL trial, offering a new CAR-T option.

⚡️ #Breyanzi, développé par #BMS, est approuvé par la #FDA pour le #Lymphome 🩸 de la zone marginale R/R

Parmi les 77 patients :

Taux de réponse global ( #ORR) : 84,4 % (IC 95 % : 74,4–91,7)
Taux de réponse complète ( #CRR) : 55,8 % (IC à 95 % : 44,1–67,2)

oncodaily.com/oncolibrary/...

The European Commission Approves Breyanzi for Relapsed/Refractory Mantle Cell Lymphoma - OncoDaily The EU has approved Breyanzi for adults with relapsed or refractory mantle cell lymphoma after BTK inhibitor therapy, based on strong responses in TRANSCEND NHL 001.

The European Commission Approves Breyanzi for Relapsed/Refractory Mantle Cell Lymphoma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lymphoma #Breyanzi

→ La catégorie la plus importante est celle des maladies #Hématologiques 🩸, qui couvrent des maladies comme le #Lymphome, le #MyélomeMultiple et l’ #Hémophilie

→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi

BREYANZI's Rising Market Presence in the CAR-T Therapy Landscape Sees Positive Trends BREYANZI is carving out a strong niche in the CAR-T therapy market. With its innovative technology and solid efficacy, sales are projected to soar in the coming years.

BREYANZI's Rising Market Presence in the CAR-T Therapy Landscape Sees Positive Trends #United_States #Las_Vegas #CAR-T_therapy #Bristol_Myers_Squibb #BREYANZI